+33(0)1 42 54 60 64 |

contact@welcomeurope.com

EU4Health Programme (EU4H) – Action Grants 2024 (HERA) – 2024

The "EU for Health" program (EU4health) is the successor to the 3rd EU Health Program. It aims to improve health in the European Union, respond to the COVID-19 health crisis and make healthcare systems more resilient.

2024-09-05
149 million euro
Close

Appeal framework

Call reference EU4H-2024-PJ-01
Program EU4 Health Programme (EU4H)
Institution European Commission
Sectors Business & Industry Civil Protection & Risks Cooperation & Development Health Research & Innovation Technology & Digital
Beneficiaries Large company (> 250 employees) Research centre & university Smes & Start-Ups (< 249 Employees)

Content reserved for subscribers

Call reference

EU4H-2024-PJ-01



Register for free to access the content

Free access to all information

Priorities and funded actions

Objectives

  • To enhance crisis preparedness and response for future health emergencies in relation to medical countermeasures, with a focus on priority pathogens with pandemic potential. It implements the EU4Health Programme’s general objective of improving the availability, accessibility and affordability of crisisrelevant products
  • To foster innovation and support development of nextgeneration respiratory PPE that overcomes the limitations outlined above and result in increased availability of enhanced medical countermeasures for pandemic preparedness and response
  • To support improved manufacturing technologies and processes that allow for a more effective, less expensive, easier to scale-up, more sustainable and cleaner production of medicines in the Union, and to support the Union’s pharmaceutical industry to be better able to respond to public health need s in the context of health emergencies and critical medicines’ shortages
  • To support the policy priority to be better prepared to respond to serious cross-border health threats

Among financed actions

  • The creation of a European Hub for public health relevant vaccine development
  • The development of support for or innovations targeting manufacturing of APIs, their intermediates and/or excipients
  • To contribute to increasingly sophisticated enhancements to chemical and/or biological processes or decreasing the production of polluting agents
  • The development of novel manufacturing processes and technologies, and novel industrial manufacturing and facility designs
  • The development and further characterisation of broadspectrum antivirals targeting identified HERA priority viral families

Eligibility

  • Be a legal person
  • Be a public or private entity
  • Be established in one of the eligible countries:
    • EU Member States (including overseas countries and territories)
    • Non-EU states: listed EEA countries and countries associated to the EU4Health Programme (list of participating countries)
  • EU4H-2024-PJ-01-1:
    • Vaccine developers including publicly funded and industrial organisations
    • Proposals must be submitted by a consortium of at least 3 applicants
  • EU4H-2024-PJ-01-2:
    • Legal entities active in the field of innovation and with adequate expertise in PPE, proven by experience in the sector (e.g. past development activities, academic research)
    • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants
  • EU4H-2024-PJ-01-3:
    • Industrial economic operators, technology developers and applied research
      stakeholders capable of developing the mentioned manufacturing technologies and processes
    • Established legal entities with a clear track record of industrial innovation development
    • Technical expertise in the area of manufacturing technologies and/or processes relevant to the call.
    • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants
  • EU4H-2024-PJ-01-4:
    • Private, academic and public bodies active and in the field of innovation and with proven expertise in development of antivirals
    • Proposals must be submitted by either a single applicant or a consortium of at least 3 applicants

Additional information

  • Initial duration of the action:
    • EU4H-2024-PJ-01-1: 48 months
    •  EU4H-2024-PJ-01-2: 48 months
    •  EU4H-2024-PJ-01-3: between 24 and 48 months
    • EU4H-2024-PJ-01-4: 24 months
  • Contact: HADEA-HP-CALLS@ec.europa.eu

Useful

Guidelines: Click here

Other call documents: Click here

Executive Agency website: Click here

More information: Click here

Financement
  • Total budget of the call: 149 million euro
  • Total budget of the topic:
    • EU4H-2024-PJ-01-1: 102 million euro
    •  EU4H-2024-PJ-01-2: 20 million euro
    •  EU4H-2024-PJ-01-3: 17 million euro
    • EU4H-2024-PJ-01-4: 10 million euro
  • Amount of the grant:
    • EU4H-2024-PJ-01-1: 102 million euro
    • EU4H-2024-PJ-01-2: 5 million euro
    •  EU4H-2024-PJ-01-3: 5.6 million euro
    • EU4H-2024-PJ-01-4: 10 million euro
  • Funding rate: 60% of the total eligible costs (80% for projects project of exceptional utility)

Similar news

25 August 2021

Webinar Horizon Europe: Guide to prepare an accurate financial statement on time

Read the article

9 June 2021

Welcomeurope’s new service!

Read the article